Drugs / SIM0501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06331559 | Mar 2024 → Sep 2025 | cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-01-16 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory SIM0501 Tablets, a USP1 Small-Molecule Inhibitor, Obtained Clinical Trial Approval in China simcere.com ↗
has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) in China. |
| 2023-12-05 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory SIM0501, SIMCERE ZAIMING’S USP1 SMALL-MOLECULE INHIBITOR APPROVED FOR CLINICAL TRIAL BY U.S. FDA simcere.com ↗
received approval by the U.S. Food and Drug Administration (FDA) for an Investigational New Drug Application (IND) for SIM0501 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-01-16 | Jiangsu Simcere Pharmaceutical Co., Ltd. | SIM0501 Tablets, a USP1 Small-Molecule Inhibitor, Obtained Clinical Trial Approval in China simcere.com ↗ |
| 2023-12-05 | Jiangsu Simcere Pharmaceutical Co., Ltd. | SIM0501, SIMCERE ZAIMING’S USP1 SMALL-MOLECULE INHIBITOR APPROVED FOR CLINICAL TRIAL BY U.S. FDA simcere.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIM0501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06331559 ↗ |